Delivery Order SPE2DP20D0002-SPE2DP25F9621
Award Date 7/14/25
Potential Completion Date 7/29/25
Potential Value $330K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- The U.S. Department of Defense's Medical Supply Chain awarded a $660,627.72 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. Issued on December 1, 2025, with an ultimate completion date of December 9, 2025, this delivery order represents one of over 150 awards the company has received since 2023 under an indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside...
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The U.S. Department of Defense's Medical Supply Chain awarded a $165,157 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order was issued without a set-aside designation and represents work to be performed at Teva's primary facility in Parsippany, New Jersey. Teva, a subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., has served as a critical federal pharmaceutical...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- Teva Pharmaceuticals USA, Inc. was awarded a delivery order valued at $660,627.72 for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price contract was issued under the Medical Supply Chain, a defense-oriented federal agency, with performance occurring at Teva's facility in Parsippany, New Jersey. The delivery order was awarded without a set-aside designation, allowing Teva to compete as a large business in an unrestricted...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...